Title: EBN Industry News– LegoChem-Astrazeneca antibiotics codevelopment and license-out contract.

Publication: EBN Industry News

Date: 02 January 2013

Summary

• LegoChem Bioscience signed an agreement with a global pharmaceutical company, AstraZeneca, on co-development and license-out of new antibiotics that can treat bacteria resistant to existing antibiotics.

• LegoChem is now developing cephalosporin antibiotics that will be injected with AstraZeneca’s medicine as a combination therapy, in order to treat antibiotics-resistant Gram-negative bacteria, such as P. aeruginosa, K. pneumoniae and A. baumannii.

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).